Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen Krupa who wrote (1149)	7/24/2000 1:37:45 PM
From: Cacaito	Read Replies (1) \| Respond to of 1386

From BOL 2Q report: ""Second-quarter revenues from the company's pharmaceuticals business were down 12% from the same period in 1999. Excluding the negative impact of foreign currency, revenues declined 8%. Sales in local currency were up 11% for the company's Dr. Mann Pharma subsidiary in Germany, and in the U.S., revenues from Lotemax(TM) and Alrex(TM), the company's proprietary ophthalmic anti-inflammatory drops, were up sharply during the quarter. These gains were more than offset by results for the company's line of generic ear drops in the U.S., where prior year results were significantly augmented by price increases taken after a major competitor's exit from the market. Revenues from these products in the second quarter of 2000 were significantly lower than a year ago, reflecting pricing activity by new competitors that was more aggressive than the company had anticipated. "" Could we expect very good numbers for Pharmos 2Q? , it does seem that BOL is probably going to put more efforts in the marketing of Alrex/Lotemax, since they are the one good part of the report, they are busy now buying a European company, after that they will push for Alrex/Lotemax. Anyway, they better do, they tanked a good 25%.